Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 483-493 , September 2006

Evidence-based management of polycythemia vera

  • Tiziano Barbui, MD (Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39 035 269 490; Fax: +39 035 266 147.
    • ,
  • Guido Finazzi, MD (Associate Professor)

References 

  1. Marchioli R, Tognoni G. The use of aspirin in polycythemia vera. In: Hematology. ASH education program book. 2003;p. 209–23
  2. Marchioli R, Finazzi G, Landolfi R, et al. Morbidity and mortality of a multicountry prospective cohort of 1638 patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232
  3. Gruppo Italiano Policitemia Vera (GISP) . Polycythemia vera: the natural history of 1213 patients followed over 20 years. Ann Intern Med. 1995;123:656–664
  4. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132–143
  5. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc. 2003;78:174–294
  6. Spivak JL. Polycythemia vera: myths, mechanisms and management. Blood. 2002;100:4272–4290
  7. Najean Y, Rain J-D. The very long term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997;34:6–16
  8. Haanen C, Mathe G, Hayat M. Treatment of polycythemia vera by radiophosphorus or busulphan, a randomized clinical trial. Br J Cancer. 1981;44:75
  9. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34:17
  10. Najean Y, Rain JD, for the French Polycythemia Study Group . Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370–3377
  11. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med. 1995;332:1132
  12. Nand S, Stock W, Godwin J, et al. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996;52:42–46
  13. Sterkers Y, Preudhomme C, Lai J-L, et al. Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616–622
  14. Hanft VN, Fruchtman SR, Pickens CV, et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95:3589–3593
  15. Shibata K, Shimamoto Y, Suga K, et al. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation—a brief review of recent literature. Acta Haematol. 1994;91:84–88
  16. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664–2670
  17. Silver RT. Interferon alpha2b: a new treatment for polycythemia vera. Ann Intern Med. 1993;119:1091–1092
  18. Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol. 2000;79:103–109
  19. Heis N, Rintelen C, Gisslinger B, et al. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol. 1999;62:27–31
  20. Gilbert HS. Long term treatment of myeloproliferative disease with interferon alpha-2b: feasibility and efficacy. Cancer. 1998;83:1205–1213
  21. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986;23:172–176
  22. Gruppo Italiano Studio Policitemia (GISP) . Low-dose aspirin in polycythemia vera: a pilot study. Br J Haematol. 1997;97:453–456
  23. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–124
  24. van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and hemorrhagic manifestations of thrombocythaemia. Presse Med. 1994;23:73–77
  25. Martyre MC. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep. 2003;2:257–263
  26. Silver RT, Fruchtman SM, Feldman EJ, et al. Imatinib mesylate (Gleevec) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. Blood. 2004;104:189a;[abstract]
  27. Najean Y, Rain J-D. for the French Polycythemia Study Group. Treatment of polycythemia vera: use of p32 alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood. 1997;89:2319–2327

PII: S1521-6926(05)00094-0

doi: 10.1016/j.beha.2005.07.007

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 483-493 , September 2006

Article Tools

* Image Usage & Resolution